Login to Your Account



Amylin, Lilly Score On First Exenatide Diabetes Phase III

By Brady Huggett


Friday, August 8, 2003
Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. released partial results from their first of three exenatide Phase III trials in Type II diabetes, disclosing enough information to show the product hit its primary endpoint and to raise Amylin's stock. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription